A61K 31/664
Amides of phosphorus acids
A61K31/664 (Amides of phosphorus acids) appears on 227 US grants and 423 published applications in this corpus.
Search patents in A61K- Granted patents
- 227
- Published applications
- 423
- Assignees
- 243
- Inventors
- 797
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 4 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 0 |
| 2002 | 1 | 4 |
| 2003 | 3 | 2 |
| 2004 | 1 | 6 |
| 2005 | 2 | 3 |
| 2006 | 1 | 4 |
| 2007 | 1 | 3 |
| 2008 | 0 | 8 |
| 2009 | 1 | 4 |
| 2010 | 4 | 19 |
| 2011 | 2 | 14 |
| 2012 | 8 | 23 |
| 2013 | 11 | 30 |
| 2014 | 20 | 28 |
| 2015 | 10 | 24 |
| 2016 | 22 | 33 |
| 2017 | 18 | 32 |
| 2018 | 16 | 17 |
| 2019 | 14 | 26 |
| 2020 | 12 | 26 |
| 2021 | 9 | 16 |
| 2022 | 9 | 26 |
| 2023 | 9 | 33 |
| 2024 | 5 | 18 |
| 2025 | 15 | 13 |
| 2026 | 11 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compounds and formulations29 Sep 2026US 12,746,248 B2Pro-Al Medico-Technologies, Inc.
- Dosing for treatment with anti-CD20/anti-CD3 bispecific antibody8 Sep 2026US 12,729,243 B2Hoffmann-La Roche Inc.
- Orally administered solid dosage form drug4 Aug 2026US 12,697,306 B2Ascentawits Pharmaceuticals, Ltd.
- Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone2 Jun 2026US 12,642,778 B2Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
- Method and composition for inhibiting virus infection26 May 2026US 12,636,272 B2Arjil Biotech Holding Company Limited
- Methods of treating pancreatic cancer27 Aug 2026US 2026/0250684 A1The Regents of the University of California
- Harnessing ikzf:beta-catenin complexes in the treatment of lymphocyte associated diseases or conditions20 Aug 2026US 2026/0240865 A1Yale University
- Treatment of pediatric cancers using gylcogen synthase kinase form b inhibitors13 Aug 2026US 2026/0232634 A1
- Modulator for promoting binding of butyrophilin 3a1/2a130 Jul 2026US 2026/0216219 A1Unicet Biotech Co. LLC.
- Transient receptor potential vanilloid 6 inhibitors23 Jul 2026US 2026/0207587 A1Uniquest Pty Limited
Most cited
By later US patents
- Combination therapies employing GITR binding molecules129US 8,591,886 B2GITR, Inc. · 2013
- Compositions and methods for treating hepatitis C virus101US 8,889,159 B2Gilead Pharmasset LLC · 2014
- Nucleoside phosphoramidates74US 8,642,756 B2Gilead Pharmasset LLC · 2014
- Methods of use of cyclopamine analogs72US 8,227,509 B2Infinity Pharmaceuticals, Inc. · 2012
- Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases62US 7,964,571 B2Egen, Inc. · 2011